Drugs / boron phenylalanine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01233492 | Oct 2007 → Sep 2013 | central nervous system neoplasm | Cancer Research UK | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | boron phenylalanine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01233492 ↗ |
| Known as | BPA | “To determine the optimal way to deliver boron phenylalanine (BPA) with or without mannitol in terms of route (intravenous vs intraarterial), blood-brain barrier disruption, and...” NCT01233492 ↗ |
| Route | Intravenous | “boron phenylalanine intravenously (IV)” NCT01233492 ↗ |